参考文献/References:
[1].Razzaque MA,Gupta M,Osinska H,et al.An endogenously produced fragment of cardiac myosin-binding protein C is pathogenic and can lead to heart failure[J].Circ Res,2013,113(5): 553-561.
[2].Barefield D,Sadayappan S.Phosphorylation and function of cardiac myosin binding protein-C in health and disease[J].J Mol Cell Cardiol,2010,48(5):866-875.
[3].Kaier TE,Twerenbold R,Puelacher C,et al.Direct comparison of cardiac myosin-binding protein C with cardiac troponins for the early diagnosis of acute myocardial infarction[J]. Circulation,2017,136(16):1495-1508.
[4].Carrier L,Mearini G,Stathopoulou K,et al.Cardiac myosin-binding protein C (MYBPC3) in cardiac pathophysiology[J].Gene,2015,573(2):188-197.
[5].Sadayappan S,de Tombe PP.Cardiac myosin binding protein-C as a central target of cardiac sarcomere signaling: a special mini review series[J].Pflugers Arch,2014, 466(2):195-200.
[6].Moss RL,Fitzsimons DP,Ralphe JC.Cardiac MyBP-C regulates the rate and force of contraction in mammalian myocardium[J].Circ Res,2015,116(1):183-192.
[7].Lynch TL,Sadayappan S.Surviving the infarct:a profile of cardiac myosin binding protein-C pathogenicity,diagnostic utility,and proteomics in the ischemic myocardium[J].Proteomics Clin Appl,2014,8(7-8):569-577.
[8].Sadayappan S,Gulick J,Osinska H,et al.A critical function for Ser-282 in cardiac Myosin binding protein-C phosphorylation and cardiac function[J].Circ Res,2011,109(2):141-150.
[9].Tong CW,Nair NA,Doersch KM,et al.Cardiac myosin-binding protein-C is a critical mediator of diastolic function[J].Pflugers Arch,2014,466(3):451-457.
[10].张晨,常静.心脏型肌球蛋白结合蛋白与射血分数保留的心力衰竭[J].心血管病学进展,2015,36(04):437-441.
[11].Nagayama T,Takimoto E,Sadayappan S,et al.Control of in vivo left ventricular [correction] contraction/relaxation kinetics by myosin binding protein C:protein kinase A phosphorylation dependent and independent regulation[J].Circulation,2007, 116(21):2399-2408.
[12].寇晓庆,常鹏,孙润民,等.心脏型肌心脏型肌球蛋白结合蛋白与射血分数保留的心力衰竭球蛋白结合蛋白-C与心血管疾病的研究进展[J].中国循环杂志,2018,33(11):1125-1127.
[13].Govindan S,Kuster DW,Lin B,et al.Increase in cardiac myosin binding protein-C plasma levels is a sensitive and cardiac-specific biomarker of myocardial infarction[J]. Am J Cardiovasc Dis,2013,3(2):60-70.
[14].Kuster DW,Cardenas-Ospina A,Miller L,et al.Release kinetics of circulating cardiac myosin binding protein-C following cardiac injury[J].Am J Physiol Heart Circ Physiol,2014,306(4): H547-H556.
[15].Maznyczka A,Kaier T,Marber M.Troponins and other biomarkers in the early diagnosis of acute myocardial infarction[J].Postgrad Med J,2015,91(1076):322-330.
[16].Govindan S,McElligott A,Muthusamy S,et al.Cardiac myosin binding protein-C is a potential diagnostic biomarker for myocardial infarction[J].J Mol Cell Cardiol, 2012,52(1):154-164.
[17].Gilda JE,Gomes AV.How phosphorylated can it get? Cardiac myosin binding protein C phosphorylation in heart failure[J].J Mol Cell Cardiol,2013,62:108-110.
[18].van Dijk SJ,Dooijes D,dos Remedios C,et al.Cardiac myosin-binding protein C mutations and hypertrophic cardiomyopathy:haploinsufficiency,deranged phosphorylation,and cardiomyocyte dysfunction[J].Circulation,2009,119(11): 1473-1483.
[19].Otto CM,Prendergast B.Aortic-valve stenosis--from patients at risk to severe valve obstruction[J].N Engl J Med,2014,371(8):744-756.
[20].Anand A,Chin C,Shah ASV,et al.Cardiac myosin-binding protein C is a novel marker of myocardial injury and fibrosis in aortic stenosis[J].Heart,2018, 104(13):1101-1108.
[21].Mohamed IA,Krishnamoorthy NT,Nasrallah GK,et al.The role of cardiac myosin binding Protein C3 in hypertrophic cardiomyopathy-progress and novel therapeutic opportunities[J].J Cell Physiol,2017,232(7):1650-1659.
[22].Li Q,Gruner C,Chan RH,et al.Genotype-positive status in patients with hypertrophic cardiomyopathy is associated with higher rates of heart failure events[J]. Circ Cardiovasc Genet,2014,7(4):416-422.
[23].Kissopoulou A,Trinks C,Green A,et al.Homozygous missense MYBPC3 Pro873His mutation associated with increased risk for heart failure development in hypertrophic cardiomyopathy[J]. ESC Heart Fail,2018,5(4):716-723.
[24].Chen PP,Patel JR,Powers PA,et al.Dissociation of structural and functional phenotypes in cardiac myosin-binding protein C conditional knockout mice[J].Circulation,2012,126(10): 1194-1205.
[25].McNally EM,Golbus JR,Puckelwartz MJ.Genetic mutations and mechanisms in dilated cardiomyopathy[J].J Clin Invest,2013,123(1):19-26.
[26].Reinstein E,Tzur S,Bormans C,et al.Exome sequencing identified mutations in CASK and MYBPC3 as the cause of a complex dilated cardiomyopathy phenotype[J]. Genet Res (Camb), 2016,98:e8.
[27].Morimoto S,Lu QW,Harada K,et al.Ca(2+)-desensitizing effect of a deletion mutation Delta K210 in cardiac troponin T that causes familial dilated cardiomyopathy[J]. Proc Natl Acad Sci U S A,2002,99(2):913-918.
[28].Lynch TL 4th,Sivaguru M,Velayutham M,et al.Oxidative stress in dilated cardiomyopathy caused by MYBPC3 mutation[J].Oxid Med Cell Longev,2015: 424751.
[29].Yuan CC,Kazmierczak K1,Liang J,et al.Hypercontractile mutant of ventricular myosin essential light chain leads to disruption of sarcomeric structure and function and results in restrictive cardiomyopathy in mice[J].Cardiovasc Res,2017,113(10):1124-1136.
[30].Wu W,Lu CX,Wang YN,et al.Novel phenotype-genotype correlations of restrictive cardiomyopathy with myosin-binding protein C (MYBPC3) gene mutations tested by next-generation sequencing[J].J Am Heart Assoc,2015,4(7):e001879.
相似文献/References:
[1]白春兰,张军.正五聚蛋白-3:新型心血管病炎性标志物[J].心血管病学进展,2016,(1):87.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.023]
BAI Chunlan,ZHANG Jun.Pentraxin-3: A Novel Inflammation Biomarker for Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2016,(7):87.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.023]
[2]任茂佳,贺文帅,张琪,等.围绝经期对心血管疾病相关危险因素的影响[J].心血管病学进展,2019,(6):911.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.018]
REN Maojia,HE Wenshuai,ZHANG Qi,et al.Effects of Perimenopause on Cardiovascular Risk Factors[J].Advances in Cardiovascular Diseases,2019,(7):911.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.018]
[3]尹琳 黄从新.JP2蛋白和心血管疾病的研究进展[J].心血管病学进展,2019,(7):1004.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.010]
YIN Lin HUANG Congxin.Research Progress of JP2 Protein and Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2019,(7):1004.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.010]
[4]朱峰 汪汉 蔡琳.抗体与心血管疾病[J].心血管病学进展,2019,(7):1007.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.011]
ZHU FengWANG HanCAI Lin.Antibodies and Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2019,(7):1007.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.011]
[5]姬楠楠 杨晓静 谢勇.单核细胞/高密度脂蛋白比值与心血管疾病的研究进展[J].心血管病学进展,2019,(7):1019.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.014]
JI Nannan YANG Xiaojing XIE Yong.Monocyte/High-density Lipoprotein Ratio and Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2019,(7):1019.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.014]
[6]渠海贤 李涛 程流泉.人工智能在心脏磁共振成像中的应用进展[J].心血管病学进展,2019,(5):659.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.001]
[7]侯冬华 郝丽荣.长正五聚蛋白3在动脉粥样硬化和心血管疾病中作用研究的新进展[J].心血管病学进展,2019,(5):805.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.035]
HOU Donghua H AO Lirong.The Study of Atherosclerosis and Cardiovascular Diseases with Pentapycin 3[J].Advances in Cardiovascular Diseases,2019,(7):805.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.035]
[8]张维 张恒 康品方.外泌体在心血管疾病中的研究进展[J].心血管病学进展,2019,(5):818.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.038]
Zhang WeiKang Pinfang.Exosome in Cardiovascular Diseases[J].Advances in Cardiovascular Diseases,2019,(7):818.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.038]
[9]韦莹 刘书旺 李蕾 崔鸣.生长分化因子-15在心房颤动中的研究进展[J].心血管病学进展,2019,(8):1073.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.001]
WEI Ying,LIU Shuwang,LI Lei,et al.Growth Differentiation Factor-15 in Development of Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2019,(7):1073.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.001]
[10]李海威 姜红 李宪伦.射血分数保留性心力衰竭患者运动康复的研究进展[J].心血管病学进展,2019,(8):1146.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.019]
LI Haiwei,JIANG Hong,LI Xianlun.Exercise Rehabilitation in Patients with Heart Failure with Preserved Ejection Fraction[J].Advances in Cardiovascular Diseases,2019,(7):1146.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.019]